ArticleVeterinary research communications2026
Antimicrobial susceptibility of E. coli isolated from dairy cow milk in Egypt and antibacterial activity of selected nanomaterials against MDR strains.
Article in Veterinary research communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Escherichia coli (E. coli) is a significant livestock and foodborne pathogen. This study was designed to isolate E. coli from raw cow milk, evaluate its antimicrobial susceptibility, and investigate the antimicrobial activity of silver nanoparticles (nAg), zinc oxide nanoparticles (nZnO), and Moringa nano-emulsion (MNE) against multidrug resistant (MDR) strains. A total of 146 individual milk samples were obtained from dairy cows in Egypt. E. coli were isolated by standard culture methods and pathotyped using molecular techniques. The antibiotic resistance of the isolates was determined, and the antimicrobial activity of the selected nanomaterials was evaluated using the broth microdilution method on the identified MDR strains. E. coli was detected in 54.8% (80/146) of the samples; 42 out of 80 (52.5%) were virulent strains, including STEC (15/42; 35.7%), ETEC (12/42; 28.57%), EPEC (12/42; 28.57%), and AE-STEC (3/42; 7.1%). The isolated strains showed the highest resistance rate to sulfa-trimethoprim (52.5%), tetracycline (45%), and ampicillin (42.5%); and the lowest against marbofloxacin (8.75%) and ceftiofur (27.5%). Overall, 42.5% of the E. coli strains exhibited MDR, including virulent and non-virulent strains at 45.2% (19/42) and 39.47% (15/38), respectively. The minimum inhibitory concentration (MIC) values against MDR E. coli isolates were lowest for nAg (1.56-12.5 µg/mL), followed by nZnO (12.5-50 µg/mL). In contrast, Moringa nano-emulsion (MNE) requires much higher concentrations (125-250 µg/mL) for growth inhibition. Raw cow milk is a potential source of pathogenic and MDR E. coli, emphasizing continuous surveillance and prudent antimicrobial use. Although selected nanomaterials showed consistent in vitro efficacy, further studies are required before considering practical veterinary applications.
Indexed as
Identifiers
42909702What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.